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  Seventeen patients with benign prostatic hypertrophy have been treated by an oral administra－
tion of phenoxybenzamine （POB） 5 mg daily for 14 days． The effectiveness was determined by scoring
the relief degree of symptoms or complaints related ！o micturiti，on， and by physical findings一 such as
the amount ef residual urine， urofiowmetric and．cystometric patterns，． and urethral pressure
profile．
  The results obtained are as follows：
  1． Relief of the symptoms or complaints was obtained in 12 patients （70．69／．）， and the decrease
of necturnal frcquency in 13 patients （76．50／．） （p〈O．Ol）．
  2． The decrease of residual urine was obtained in 12 patients （70．60／．）．
  3． The estimation of posterior urethral pressure was undertaken in 4 Patients and there was no
significant decrease after the administration．
  4． Neither subjective nor－objective side effects wefe．observed in the patients．


















































Table 1． Scoring for evaluation．
















































        成     績
a）自覚症状に対する効果
 Table 2のごとく，著効3例（17・6％），有効6例
Table 2． Effect of POB on subJ’ective symptoms．
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Table 3． Effect of POB on，’Tresidual urine etc．
cose Nocturia XP／inUeMe（ llif］3eSidUai Residud rotio cei．）
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Tabie 4． Effect of POB on uroflowmetric findings．
・。se鷺、鯉畿；1α〃魔・・rne・…麗長子fl㎝鵬厩・…
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Table 5． Effect of POB on cystometric findings．
   First desire to void Strong cJesire to vekl Max．wo’tl’ng pressite
Cose  ｛mけ   【ml）   〔mmHg｝














































































Table 6． Effect of POB cn urethral pressure pronle
   Urethral length
CaSe trnm）
No．
Ure奄モ?高窒nA2Pore）5SUre up rnax ｛cmH20）





22，8 20 2S IOO 7S
？6．4 15 15 65 85
5i．2 2S 50 95 110












Fig． 1． Urethral pressure profile before and after POB treatment．
Table 7． Effect of POB on blood pressure．
   Supine Plood ． SMing PloodCase   pressure （mm／Hg｝ pressu－fe （rnrn／Hg）
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 Regi七ine 2mg
Fig． 2． Effect of vegitine on blood
    urethral pressure．
pr ssure and
614 勝見・ほか：前立腺肥大症・POB
Table 8． Effect of ’regitine on urethral and blood
     pressure．
Beiore After odnninistrahon
 edrn，n，stration ot 2mg regitZne．
UP 8P
Table 9． Effect’of papaverine HCI （Pap．） on
     response to nor－adrenalin （NA） in urethral
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